Laekna, Inc, a biotechnology company, announced today that it acquires world-wide rights from Novartis for an CYP17 inhibitor (CFG920) for the treatment of prostate cancer. CFG920 is an oral drug candidate of androgen inhibitor. Novartis has conducted a clinical “proof of concept” study in metastatic castration resistant prostate cancer patients and received positive results.
